MTOR and colorectal cancer: In agreement with our observation, it was recently described that Met transiently inhibits colorectal cancer cell proliferation and clonogenicity through AMPK activation and increase ROS production, which suppressed the mTOR pathway and its downstream targets S6 and 4EBP159.